Table 1.
Clinical Information of the Bladder Cancer Patients Utilized for Serum Profiling Using Custom-Made Antibody Arrays
| Case | Set 1 ID | Set 2 ID | Status | Time | Age | Sex | Stage | Grade | Node | VI | CIS | SQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1000-B | 59669A | 59705A | NED | 24 | 64 | M | PT2 | High | No | No | Yes | No |
| 1001-B | 59669B | 59705B | NED | 6.7 | 42 | M | PTA | High | No | No | No | No |
| 1002-B | 59668A | 59706A | DOD | 4 | 58 | F | PT3B | High | Yes | Yes | Yes | Yes |
| 1003-B | 59668B | 59706B | NED | 20.2 | 64 | M | PT3B | High | Yes | No | Yes | No |
| 1004-B | 59764A | 59707A | NED | 11.7 | 68 | M | PT1 | High | No | No | No | No |
| 1008-B | 59764B | 59707B | NED | 21.8 | 43 | M | PTIS | High | No | No | Yes | No |
| 1009-B | 59763A | 59708A | NED | 20 | 69 | M | PTIS | High | No | No | Yes | No |
| 1011-B | 59763B | 59708B | NED | 22.3 | 78 | F | PT3B | High | No | No | Yes | Yes |
| 1012-B | 59762A | 59709A | NED | 19.8 | 69 | M | PTA | High | No | No | No | No |
| 1013-B | 59762B | 59709B | NED | 19 | 75 | M | PT1 | High | No | No | No | No |
| 1014-B | 59667A | 59710A | NED | 22 | 73 | M | PT1 | High | No | No | Yes | No |
| 1015-B | 59667B | 59710B | NED | 19 | 69 | F | PT2 | High | No | No | Yes | No |
| 1016-B | 59666A | 59711A | NED | 21.2 | 66 | F | PT4 | High | Yes | Yes | No | Yes |
| 1017-B | 59666B | 59711B | NED | 21 | 65 | F | PTIS | High | No | No | Yes | No |
| 1018-B | 59665A | 59712A | NED | 22.2 | 61 | M | PTA | Low | No | No | No | No |
| 1019-B | 59665B | 59712B | NED | 19.8 | 68 | M | PT3B | High | No | No | No | No |
| 1020-B | 59761A | 59713A | NED | 13.4 | 75 | M | PT1 | High | No | No | No | No |
| 1021-B | 59761B | 59713B | NED | 16 | 70 | F | PT1 | High | Yes | No | Yes | No |
| 17161-B | 59752A | 57850A | DOD (#) | 38.2 | 71 | M | PTA | High | No | No | Yes | No |
| 17162-B | 59757A | 59718A | DOD | 52 | 75 | M | PT1 | High | No | No | No | No |
| 17168-B | 59753B | 59722B | DOD | 8.7 | 74 | F | PT3B | High | Yes | Yes | Yes | No |
| 17195-B | 59759B | 59716B | DOD | 31.7 | 49 | M | PT1 | High | No | No | No | No |
| 17199-B | 59755B | 59720B | NED | 25.3 | 63 | M | PTIS | High | No | No | Yes | No |
| 17208-B | 59754B | 59721B | DOD | 38.7 | 79 | M | PTIS | High | No | No | Yes | Yes |
| 17224-B | 59754A | 59721A | DOD | 6.8 | 80 | M | PTIS | High | Yes | No | Yes | Yes |
| 17229-B | 59755A | 59720A | NED | 96.6 | 64 | M | PT3A | High | No | No | No | No |
| 17230-B | 59753A | 59722A | NED | 56.1 | 62 | M | PTA | High | No | No | No | No |
| 17231-B | 59756B | 59719B | DOD | 5.5 | 67 | M | PT3B | High | No | Yes | Yes | Yes |
| 17237-B | 59757B | 59718B | DOD (*) | 36 | 79 | M | PTA | Low | No | No | No | No |
| 17238-B | 59756A | 59719A | DOD | 29.2 | 53 | F | PTIS | High | No | No | Yes | No |
| 17240-B | 59758B | 59717B | DOD | 2 | 60 | M | PT1 | High | Yes | Yes | Yes | Yes |
| 17242-B | 59758A | 59717A | DOD | 24.3 | 74 | M | PT1 | High | No | No | Yes | No |
| 17246-B | 59759A | 59716A | NED | 93.6 | 67 | M | PTA | Low | No | No | No | No |
| 17251-B | 59746B | 59715B | NED | 36 | 70 | M | PTA | Low | No | No | No | No |
| 17267-B | 59746A | 59715A | DOD | 9.4 | 50 | M | PT4 | High | Yes | Yes | Yes | Yes |
| 17270-B | 59760A | 59714A | NED | 87.2 | 75 | M | PTIS | Low | No | No | Yes | No |
| 17280-B | 59760B | 59714B | DOD | 24 | 52 | M | PTIS | High | No | No | Yes | No |
The table includes the identification of the bladder cancer cases in each set of antibody arrays (set 1 ID and set 2 ID), their overall survival status (NED, no evidence of disease; DOD, dead of disease), follow-up time (months), age (years), sex (F, female; M, male), histopathological stage, tumor grade, as well as the presence of lymph node metastases, vascular invasion (VI), carcinoma in situ (CIS), and squamous differentiation (SQ). Two patients with Ta lesions died of disease; one of them
presenting carcinoma in situ, tumor progression, and dying of bladder cancer. The other patient
had a high grade Ta, recurred, and died of the disease.